Neuromuscular

Neurology News Network. for the week ending August 16, 2025. [WATCH TIME: 4 minutes]

Novartis revealed promising phase 3 trial results for ianalumab, a potential first treatment for Sjögren’s disease, showing significant disease activity reduction.

Catch up on any of the neurology news headlines you may have missed over the course of July 2025, compiled all into 1 place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Daniel Freedman, PhD, of MIT, gave clinical commentary on how Openwater’s Open-LIFU enables new research into conscious perception and potential clinical applications for conditions like pain and depression.

Vertex Pharmaceuticals halts VX-993 development for acute pain after phase 2 trial shows no significant efficacy compared with placebo.

The neurologist at Duke Health provided insights on how chronic demyelinating inflammatory polyneuropathy treatment is evolving toward biomarker-driven, personalized approaches at the 2025 Carolina Neuromuscular Summit. [WATCH TIME: 2 minutes]

The director of the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital gives clinicians insight on the reasons to attend the 2025 Carolina Neuromuscular Summit. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 1, 2025.

Capricor Therapeutics navigates FDA challenges for deramiocel, aiming to advance treatment for DMD-related cardiomyopathy with promising trial data.

Roche faces regulatory challenges for Elevidys, an approved gene therapy for Duchenne muscular dystrophy, amid safety concerns and clinical trial setbacks.

Here's some of what is coming soon to NeurologyLive® this week.

A new phase 3 study will explore masitinib's potential as treatment for ALS, aiming to enhance patient outcomes and confirm earlier promising results.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 25, 2025.

AstraZeneca's gefurulimab shows promising results in treating generalized myasthenia gravis, offering patients a convenient, self-administered therapy option.

Neurology experts anticipate groundbreaking clinical trial results in 2025, potentially transforming treatment strategies for various neurological conditions.

Members from Nuvig Therapeutics discussed the rationale and therapeutic development of NVG-2089, a novel anti-inflammatory agent being studied for chronic inflammatory demyelinating polyneuropathy.

The FDA-cleared devices allow for a more simplified administration of the liquid medicine Hyqvia, reducing the number of steps needed to prepare for the infusion of 2 dual vial units or more.

Here's some of what is coming soon to NeurologyLive® this week.

FDA halts Sarepta's Elevidys gene therapy distribution after three patient deaths, prioritizing safety amid ongoing clinical trial evaluations.

Elisabeth Marsh, MD, an associate professor of neurology at Johns Hopkins, shared her insights on the emerging role of AI in clinical practice and neurologic education, ahead of her session at the 2025 ANA/AUPN Annual Meetings.

Nuri Jacoby, MD, neurologist at Maimonides Medical Center and SUNY Downstate, previewed a hands-on session at the upcoming AUP Annual Meeting exploring how simulations can teach communication, professionalism, and feedback skills in neurology training.

Nester Tomycz, MD, director of neurosurgical pain division at Allegheny General Hospital, discussed emerging neurosurgerical approaches for chronic pain, with a focus on neuromodulation, patient selection, and non-opioid treatment pathways.

Recently reported phase 2b results revealed that PrimeC consistently altered ALS-related miRNA expression, reinforcing its potential as a multi-targeted therapy and aligning with previously reported clinical benefits.